[Activation and functions of blood platelets in patients with diabetes mellitus type 1 before and during the treatment with indobufen].
In 18 patients with type I diabetes the effect was studied of 10 days of Indobufen administration in daily doses of 400 mg on the activation and function of platelets. Spontaneous and ADP and adrenaline-induced aggregation, adhesiveness, platelet factors 3 and 4, and generation of malonyldialdehyde (MDA) in platelets were investigated. The results were compared with similar results in the same group prior to the treatment and in a control group of 19 healthy subjects. Highly significant inhibition was noted of spontaneous inhibition and that evoked by adrenaline and ADP, and a considerable reduction of MDA generation by platelets. These results indicate that the new platelet inhibitor--Indobufen, effectively inhibiting platelet activation and function may prevent development of thrombotic complications of diabetes.
Dmoszyńska-Giannopoulou
A
A
Kliniki Hematologii Instytutu Chorób Wewnetrznych AM w Lublinie.
Sokołowska
B
B
Ledwozyw
A
A
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000150:complications; D003925:Diabetic Angiopathies / Q000517:prevention & control*; D005260:Female; D006801:Humans; D054833:Isoindoles; D008297:Male; D008875:Middle Aged; D010654:Phenylbutyrates / Q000008:administration & dosage*; D010974:Platelet Aggregation / Q000187:drug effects / Q000502:physiology*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D013927:Thrombosis / Q000517:prevention & control*
D054833:Isoindoles; D010654:Phenylbutyrates; D010975:Platelet Aggregation Inhibitors; C020371:indobufen
Aktywacja i czynność krwinek płytkowych u chorych na cukrzyce typu I przed i w czasie leczenia indobufenem.